Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(147 produtos)
- Bcr-Abl(103 produtos)
- EGFR(572 produtos)
- FAK(71 produtos)
- FLT(91 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(87 produtos)
- Src(80 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(262 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1522 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
SUN13837
CAS:<p>SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.</p>Fórmula:C21H29N5O2Cor e Forma:SolidPeso molecular:383.49INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Fórmula:C19H11Cl2N5Cor e Forma:SolidPeso molecular:380.23TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Fórmula:C18H17N5O3SCor e Forma:SolidPeso molecular:383.42EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Fórmula:C26H23N5O3Cor e Forma:SolidPeso molecular:453.49FLT3-IN-18
CAS:<p>FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.</p>Fórmula:C26H36N8OCor e Forma:SolidPeso molecular:476.62(R)-Elsubrutinib
CAS:<p>(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is used in research on immune diseases and cancer.</p>Fórmula:C17H19N3O2Cor e Forma:SolidPeso molecular:297.35EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SCor e Forma:SolidPeso molecular:658.64DMPQ dihydrochloride
CAS:<p>PDGFRβ inhibitor</p>Fórmula:C16H16Cl2N2O2Pureza:99.51%Cor e Forma:SolidPeso molecular:339.22VEGFR2 Kinase Inhibitor II
CAS:<p>VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.</p>Fórmula:C17H15BrN2OCor e Forma:SolidPeso molecular:343.22PF-06651481-00
CAS:<p>PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.</p>Fórmula:C26H29Cl2N5O3Pureza:97.01%Cor e Forma:SolidPeso molecular:530.45BLK degrader 1
CAS:<p>BLK degrader 1 is a BLK degrader with anticancer activity for cancer research.</p>Fórmula:C32H25F3N6O2Pureza:99.22% - 99.24%Cor e Forma:SolidPeso molecular:582.58BLK-IN-1
CAS:<p>BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.</p>Fórmula:C29H23F3N6O3Cor e Forma:SolidPeso molecular:560.53Atopaxar
CAS:<p>Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Fórmula:C29H38FN3O5Pureza:97.07% - 98.07%Cor e Forma:SolidPeso molecular:527.63EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Cor e Forma:SolidPeso molecular:569.67FLT3/D835Y-IN-1
CAS:<p>FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.</p>Fórmula:C22H21N5O3Cor e Forma:SolidPeso molecular:403.43GDC-0834 S-enantiomer
CAS:<p>GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C33H36N6O3SPureza:98%Cor e Forma:SolidPeso molecular:596.74TGFBR1-IN-1
CAS:TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM).Fórmula:C23H17N5O2SPureza:98%Cor e Forma:SolidPeso molecular:427.48Tyrphostin 51
CAS:<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Fórmula:C13H8N4O3Pureza:98%Cor e Forma:SolidPeso molecular:268.23TUL01101
CAS:<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Fórmula:C22H25F2N5O2Cor e Forma:SolidPeso molecular:429.46HS-438
CAS:<p>HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.</p>Fórmula:C17H17N3O3SCor e Forma:SolidPeso molecular:343.4EGFR-IN-56
CAS:<p>EGFR-IN-56 (13a) inhibits EGFR, EGFRT790M (IC50: 541.7nM), EGFRT790M/L858R (IC50: 132.1nM), blocks G2/M phase, and triggers apoptosis.</p>Fórmula:C23H22N4O3SCor e Forma:SolidPeso molecular:434.51PP2 Analog
CAS:PP2 Analog is an analog of PP2. It also acts as a protein trafficking modulator.Fórmula:C16H17ClN4Pureza:98%Cor e Forma:SolidPeso molecular:300.79EGFR-IN-60
CAS:<p>EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.</p>Fórmula:C28H28Cl2N6OCor e Forma:SolidPeso molecular:535.47ALK-IN-21
CAS:<p>ALK-IN-21 (B10) inhibits ALK WT (IC50: 4.59nM), L1196M (2.07nM), G1202R (5.95nM); curbs Karpas299, H2228 cell growth; for ALCL research.</p>Fórmula:C35H45ClN6O6S4Cor e Forma:SolidPeso molecular:809.48Sch 13835
CAS:<p>Sch 13835 is an inhibitor of platelet derived growth factor.</p>Fórmula:C15H10ClNO4SPureza:98%Cor e Forma:SolidPeso molecular:335.76Cyt-PTPε Inhibitor-1
CAS:Cyt-PTPε Inhibitor-1 (A Inhibitor-1) is an inhibitor of cytosolic protein tyrosine phosphatase ε.Fórmula:C19H20N4O2SPureza:99.55% - 99.82%Cor e Forma:SolidPeso molecular:368.45ZT55
CAS:<p>ZT55: Oral JAK2 inhibitor, IC50: 0.031 μM, hinders JAK2 V617F HEL cell growth, induces apoptosis, arrests cell cycle, effective in mice HEL tumor studies.</p>Fórmula:C17H16N2O3Cor e Forma:SolidPeso molecular:296.32VEGFR-2-IN-24
CAS:<p>VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.</p>Fórmula:C28H23N3O6SCor e Forma:SolidPeso molecular:529.56FGFR4-IN-11
CAS:<p>FGFR4-IN-11: selective, covalent FGFR4 inhibitor; IC50=2.1 nM; blocks FGF19 pathway; anticancer.</p>Fórmula:C29H29N5O5Cor e Forma:SolidPeso molecular:527.57c-Met-IN-14
CAS:<p>c-Met-IN-14: selective c-Met kinase inhibitor, IC50 2.89 nM, anticancer, stops G2/M phase, induces A549 cell apoptosis.</p>Fórmula:C34H38ClFN4O7SCor e Forma:SolidPeso molecular:701.2EGFR-IN-26
CAS:<p>EGFR-IN-26 is an EGFR inhibitor that can be used in cancer research.</p>Fórmula:C29H34N6O3Cor e Forma:SolidPeso molecular:514.62TRK/ALK-IN-1
<p>TRK/ALK-IN-1: Potent dual TRK & ALK inhibitor; IC50s: 2.2nM (TRKA), 9.3nM (ALK WT), 38nM (ALK L1196M); cancer research potential.</p>Fórmula:C31H35ClF2N8O2SCor e Forma:SolidPeso molecular:657.18FGFR3-IN-1
CAS:<p>FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM) and FGFR3 (IC50: 12 nM).</p>Fórmula:C28H39N9O3SCor e Forma:SolidPeso molecular:581.73HZ-A-005
CAS:<p>HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.</p>Fórmula:C25H23ClN6O2Cor e Forma:SolidPeso molecular:474.94VEGFR-2-IN-28
CAS:<p>VEGFR-2-IN-28 is a potent inhibitor of VEGFR-2 (IC50: 0.83 μM). VEGFR-2-IN-28 induces apoptosis and exhibits antitumor effects.</p>Fórmula:C26H17N7O7Cor e Forma:SolidPeso molecular:539.46JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Fórmula:C27H28F2N6O3Cor e Forma:SolidPeso molecular:522.55EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SCor e Forma:SolidPeso molecular:413.45TIE-2/VEGFR-2 kinase-IN-1
CAS:<p>TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.</p>Fórmula:C13H11N3O2Cor e Forma:SolidPeso molecular:241.25ON 146040
CAS:ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.Fórmula:C24H23N7O3SPureza:97.39%Cor e Forma:SolidPeso molecular:489.55Erbstatin
CAS:<p>Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.</p>Fórmula:C9H9NO3Cor e Forma:SolidPeso molecular:179.17PD-173956
CAS:<p>PD-173956 is an inhibitor of the Src family tyrosine kinases.</p>Fórmula:C20H13Cl2FN4OCor e Forma:SolidPeso molecular:415.25MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Fórmula:C55H71ClFN9O7SCor e Forma:SolidPeso molecular:1056.72EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Cor e Forma:SolidPeso molecular:526.42JAK3-IN-1
CAS:JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.Fórmula:C26H30ClN7O2Cor e Forma:SolidPeso molecular:508.02(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Fórmula:C15H19N5OCor e Forma:SolidPeso molecular:285.34CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Fórmula:C15H21N5O2Cor e Forma:SolidPeso molecular:303.36FGFR3-IN-5
CAS:<p>FGFR3-IN-5: potent, selective FGFR3 inhibitor. IC50: 3 nM FGFR3, 44 nM FGFR2, 289 nM FGFR1. For cancer research.</p>Fórmula:C24H24FN7O3Cor e Forma:SolidPeso molecular:477.49AFG206
CAS:AFG206 is the novel first-generation type II" FLT3 inhibitor."Fórmula:C20H19N3O2Cor e Forma:SolidPeso molecular:333.38Tarlox-TKI
CAS:Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.Fórmula:C19H18BrClN6OPureza:97.03%Cor e Forma:SolidPeso molecular:461.74S116836
CAS:<p>S116836 is a tyrosine kinase inhibitor.</p>Fórmula:C27H21F3N6OPureza:98%Cor e Forma:SolidPeso molecular:502.49
